376270 · KOSDAQ · ₩376270 · HEM파마
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−73.1% from the high
₩25,350Today: ₩25,350 – ₩26,550₩97,500
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
HEM Pharma (HEM파마, KRX: 376270) is listed on KOSDAQ, in the Biotech & Pharma sector. HEM Pharma is a Korean microbiome-focused healthcare company that uses its proprietary PMAS microbiome simulation technology to run three businesses: personalized healthcare services (such as the my LAB microbiome analysis and probiotic solution offered with Amway), an LBP (live biotherapeutic product) discovery platform for pharmaceutical partners, and the LABOREVE dermocosmetic skincare brand. Its shares closed at ₩26,200 on Oct 30, 2026, up 0.19% on the day, giving it a market value of ₩189B.
HEM Pharma is a Korean microbiome-focused healthcare company that uses its proprietary PMAS microbiome simulation technology to run three businesses: personalized healthcare services (such as the my LAB microbiome analysis and probiotic solution offered with Amway), an LBP (live biotherapeutic product) discovery platform for pharmaceutical partners, and the LABOREVE dermocosmetic skincare brand. The company has begun expanding into Hong Kong, Vietnam and Japan, and it is preparing for further overseas markets.
Written by AI from the company's latest annual report.
Predicted impact: Low· Actual: −3.1% vs sector, volume 0.9× normal (5 trading days)
Partnership and health-system commentary in a feature article; no size disclosed.
Titles in Korean until English translations are added.
Also known as: HEM Pharma / HEM파마 / 376270 / KRX:376270
Source: KRX statistical information